ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex
ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex
Citas y referencias (10)
Invitrogen™

ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex

El panel 1 de control de inmunooncología humana 14-Plex ProcartaPlex permite la investigación sobre el cáncer mediante el análisis deMás información
Have Questions?
Número de catálogoCantidad
EPX14A-15803-90196 pruebas
Número de catálogo EPX14A-15803-901
Precio (MXN)
-
Cantidad:
96 pruebas

El panel 1 de control de inmunooncología humana 14-Plex ProcartaPlex permite la investigación sobre el cáncer mediante el análisis de 14 proteínas diana mediante la tecnología Luminex xMAP. Este panel permite la detección simultánea de las formas solubles de proteínas que desempeñan un papel crucial en la regulación de los linfocitos T, lo que conduce al agotamiento o estimulación de los linfocitos T, modificando así la respuesta inmune antitumoral. El análisis de estos biomarcadores solubles podría ayudar a arrojar luz sobre la biología de las vías. Complementa al panel 2 de control de inmunooncología 14-plex ProcartaPlex (Cat. EPX140-15815-901) y al panel 3 de inmunooncología 9-plex ProcartaPlex (Cat. EPX090-15820-901) proporcionando 23 proteínas diana adicionales en la misma área de investigación.

Los paneles preconfigurados ProcartaPlex se han probado exhaustivamente para determinar la capacidad combinatoria, la interferencia y la reactividad cruzada de los analitos con el fin de proporcionar el mayor nivel de validación y precisión. Todos los paneles ProcartaPlex se suministran con los reactivos necesarios para realizar el ensayo.

Lista de objetivos [región de gránulos]:
Inmunoestimulante: CD27 [27], CD28 [15], CD137 (4-1BB) [26], GITR [57], HVEM [36]
Inmunoinhibidor: BTLA [52], CD80 [61], CD152 (CTLA4) [33], IDO [46], LAG-3 [47], PD-1 [65], PD-L1 [66], PD-L2 [67], TIM-3 [14]

Acerca de los ensayos ProcartaPlex para la plataforma Luminex
Los inmunoensayos ProcartaPlex se basan en los principios de un ELISA tipo sándwich y utilizan dos anticuerpos altamente específicos que se enlazan a diferentes epítopos de una proteína para cuantificar todas las proteínas diana de forma simultánea utilizando un instrumento Luminex. Para los ensayos ProcartaPlex multiplex se requieren tan solo 25 μl de plasma o suero, o 50 μl de sobrenadante del cultivo celular, y solo se necesitan cuatro horas para obtener los resultados analizados.

Las características incluyen:
• Resultados reproducibles y fiables: validados como panel según el estándar más alto del sector que incluye pruebas de combinación de objetivos de proteínas y reactividad cruzada
• Más resultados por muestra: miden múltiples objetivos de proteínas simultáneamente en una única muestra de 25–50 μl
• Plataforma de multiplexación de tecnología Luminex bien establecida de alta referencia para la detección y cuantificación de proteínas

Los ensayos de ProcartaPlex utilizan la tecnología Luminex xMAP (perfil multianalito) para la detección y cuantificación simultáneas de hasta 65 objetivos proteicos en una sola muestra de plasma, suero, sobrenadantes de cultivo celular y otros fluidos corporales de 25–50 μl.

Las microesferas de Luminex del ensayo de ProcartaPlex se tiñen internamente con proporciones precisas de fluoróforos rojos e infrarrojos para crear firmas específicas que pueden ser identificadas por los sistemas de detección Luminex xMAP (por ejemplo, Luminex 200, FLEXMAP 3D y MAGPIX). El ensayo ProcartaPlex, similar a un ELISA tipo sándwich, utiliza pares de anticuerpos emparejados para identificar la proteína de interés. En un ensayo multiplex, cada gránulo espectralmente único se etiqueta con anticuerpos específicos para una sola proteína diana, y las proteínas vinculadas se identifican con anticuerpos biotinilados y estreptavidina–R-ficoeritrina (RPE). La conjugación de anticuerpos específicos de proteínas en un gránulo distinto permite el análisis de varios elementos diana en un solo pocillo.

La diferencia más significativa entre un ensayo ProcartaPlex y uno ELISA es que el anticuerpo de captura del ensayo ProcartaPlex se conjuga en un gránulo y no se adsorbe en el pocillo de la microplaca, por lo que los reactivos del ensayo ProcartaPlex flotan en la solución.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Intervalo del ensayoVer certificado de análisis
Sensibilidad del ensayoMenos del 15 %
Método de detecciónFluorescente
Para utilizar con (equipo)Instrumentos Luminex™
FormatoKit multiplex
Línea de productosProcartaPlex
Tipo de muestraSobrenadantes de cultivo celular, suero y plasma, Plasma, Cell Culture Supernatants
Volumen de muestraSuero, plasma: 25 μl; CCS: 50 μl
Condiciones de envíoHielo húmedo
CombinabilityCombinable
Tipo de productoPanel 1 de control de inmunooncología
Cantidad96 pruebas
Research AreaImmunology, Oncology
EspecieHumano
Unit SizeEach
Contenido y almacenamiento
  • 2 viales de mezcla estándar humana L (liofilizada)
  • 1 vial de mezcla de gránulos de captura (1X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada (50 X)
  • 1 frasco de tampón de lectura (1X)
  • 1 frasco de tampón de lavado (10X)
  • 1 frasco de estreptavidina-PE (1X)
  • 1 frasco de tampón de ensayo universal (1X)
  • 1 frasco de diluyente de anticuerpos de detección (1X)
  • Tira de 8 tubos
  • Película adhesiva
  • Placa de 96 pocillos de fondo plano, negra
  • Almacenar entre 2 °C y 8 °C

Preguntas frecuentes

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

View all ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex FAQs

Citations & References (10)

Citations & References
Abstract
Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.
Authors:Rodrigues-Santos P,Almeida JS,Sousa LM,Couceiro P,Martinho A,Rodrigues J,Fonseca R,Santos-Rosa M,Freitas-Tavares P,Casanova JM
Journal:Frontiers in immunology
PubMed ID:40007535
Soft tissue sarcomas (STS) encompass over 50 histologic subtypes, representing more than 1% of solid tumors. Standard treatments include surgical resection and therapies such as anthracyclines or trabectedin for advanced cases, though challenges persist due to the tumor microenvironment’s complexity and limited immune profiling data. This study evaluates Trabectedin therapy ... More
Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
Authors:J. Gorgulho et al.
Journal:British Journal of Cancer
PubMed ID:38233492
The search for biomarkers to identify suitable candidates for immune checkpoint inhibitor (ICI) therapy remains ongoing. We evaluate how soluble levels of the next generation immune checkpoint Lymphocyte Activation Gene-3 (sLAG-3) and its association with circulating T lymphocyte subsets could pose as a novel biomarker to predict outcome to ICI ... More
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.
Authors:Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, Cañadas I, Thai TC, Kitajima S, Chiono V, Paweletz CP, Barbie DA, Kamm RD, Jenkins RW
Journal:Lab Chip
PubMed ID:30183789
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non-tumor cell elements of the tumor microenvironment ... More
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Authors:Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Bohnet S, Latz E, Ribbat-Idel J, Franklin BS, Wollenberg B
Journal:Oncotarget
PubMed ID:29937998
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patients with various cancer types. However, there ... More
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Authors:Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, Wu X
Journal:J Immunother Cancer
PubMed ID:31783776
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. With the exception of a few candidate biomarkers, the prognostic role of soluble immune checkpoint-related proteins in clear cell renal cell cancer (ccRCC) patients is largely uninvestigated. ... More
View all ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex citations